This is the authors' abstract. We don't add key points for this paper.
Our findings suggest that scFvs derived from different antibodies have distinctive characteristics, and stable expression and appropriate affinity are critical for robust antitumor efficacy. This study highlights the importance of selecting an optimal scFv in CAR-T cell design for effective CEA-targeted therapy. The identified optimal scFv, M5A, could be potentially applied in future clinical trials of CAR-T cell therapy targeting CEA-positive carcinoma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: